Atlas Brown Inc. Raises Stock Position in Pfizer Inc. $PFE

Atlas Brown Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 79,732 shares of the biopharmaceutical company’s stock after purchasing an additional 2,929 shares during the period. Atlas Brown Inc.’s holdings in Pfizer were worth $1,933,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter valued at about $27,000. North Capital Inc. bought a new position in shares of Pfizer during the 1st quarter valued at about $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer during the 1st quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. bought a new position in shares of Pfizer during the 4th quarter valued at about $30,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PFE. Berenberg Bank lowered their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. HSBC lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America increased their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.12.

Pfizer Stock Down 3.8%

Shares of NYSE PFE opened at $23.91 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market cap of $135.94 billion, a P/E ratio of 12.72, a PEG ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm has a 50-day simple moving average of $24.79 and a two-hundred day simple moving average of $24.27.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.